

**Baxter International Inc.**  
**Net Sales from Continuing Operations**  
**Period Ending June 30, 2004**  
(unaudited)

(\$ in millions)	Q2 2004	Q2 2003	% Growth @ Actual Rates	% Growth @ Constant Rates	YTD 2004	YTD 2003	% Growth @ Actual Rates	% Growth @ Constant Rates
<b>BioScience</b>								
United States	\$403	\$323	25%	25%	\$788	\$663	19%	19%
International	490	450	9%	0%	915	850	8%	(3%)
<b>Total</b>	<b>\$893</b>	<b>\$773</b>	<b>16%</b>	<b>11%</b>	<b>\$1,703</b>	<b>\$1,513</b>	<b>13%</b>	<b>6%</b>
<b>Medication Delivery</b>								
United States	\$589	\$573	3%	3%	\$1,123	\$1,093	3%	3%
International	417	365	14%	6%	812	695	17%	6%
<b>Total</b>	<b>\$1,006</b>	<b>\$938</b>	<b>7%</b>	<b>4%</b>	<b>\$1,935</b>	<b>\$1,788</b>	<b>8%</b>	<b>4%</b>
<b>Renal</b>								
United States	\$102	\$101	0%	0%	\$202	\$197	2%	2%
International	378	351	8%	2%	748	662	13%	5%
<b>Total</b>	<b>\$480</b>	<b>\$452</b>	<b>6%</b>	<b>1%</b>	<b>\$950</b>	<b>\$859</b>	<b>10%</b>	<b>4%</b>
<b>Baxter International Inc.</b>								
United States	\$1,094	\$ 997	10%	10%	\$2,113	\$1,953	8%	8%
International	1,285	1,166	10%	3%	2,475	2,207	12%	2%
<b>Total</b>	<b>\$2,379</b>	<b>\$2,163</b>	<b>10%</b>	<b>6%</b>	<b>\$4,588</b>	<b>\$4,160</b>	<b>10%</b>	<b>5%</b>

As noted in the press release, the company plans to restate its financial results back to 2001. The prior quarter and/or year-to-date results shown above do not yet reflect the restatement or the effects thereof and should be read accordingly.